1. Home
  2. DTIL

DTIL

Precision BioSciences Inc.

Logo Precision BioSciences Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-19-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.

Founded: 2006 Country:
United States
United States
Employees: 109 City: DURHAM
Market Cap: 67.4M IPO Year: 2019
Target Price: $60.00 AVG Volume (30 days): 127.2K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -15.96 EPS Growth: N/A
52 Week Low/High: $8.25 - $28.44 Next Earning Date: 05-07-2024
Revenue: $48,727,000 Revenue Growth: 94.15%
Revenue Growth (this year): -48.92% Revenue Growth (next year): -12.05%

Share on Social Networks:

Stock Insider Trading Activity of Precision BioSciences Inc. (DTIL)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Scimeca Dario DTIL General Counsel and Secretary Jan 20 '24 Sell $0.36 21,287 $7,663.32 151,028 SEC Form 4
SMITH J. JEFFERSON DTIL Chief Research Officer Jan 20 '24 Sell $0.37 28,000 $10,360.00 1,987,269 SEC Form 4
Kelly John Alexander DTIL Chief Financial Officer Aug 18 '23 Buy $0.48 90,000 $43,200.00 383,340 SEC Form 4